Integrated BioPharma Reports Decrease in Quarterly Revenue

Integrated BioPharma, Inc. (OTCQX:INBP) has released its financial results for the quarter ending March 31, 2026. The company reported a significant decline in revenue, posting $10.1 million, down from $13.9 million during the same period in 2025, marking a 27.3% decrease. The organization also shifted from an operating income of $0.7 million in 2025 to an operating loss of $1.1 million in 2026.

For the nine-month period ending March 31, 2026, revenue totaled $34.1 million, compared to $40.2 million in the previous year, a reduction of 15.2%. This period recorded an operating loss of $1.8 million, contrasting with a $1.4 million income in 2025. Net losses were $0.8 million for the quarter and $1.5 million for the nine months, with a per share loss of $(0.03) and $(0.05) respectively.

The decline was attributed to reduced income from the contract manufacturing segment's largest customers, accounting for 90% of revenue in the recent periods. Despite the challenges, executives maintain operations across manufacturing, distributing, and sales of vitamins and nutritional supplements.